// App-Quantinova.ai

BSH2020‐PO‐040 : Final results from the apixaban length‐of‐stay pulmonary embolism study ‐ Hospital Admissions (ALPHA‐PE)

Researchers

Presenter

  • R. Alikhan

Principal Investigators

  • C. Church

  • S. Shapiro

  • S. Lister

  • N. Smith

  • S. Chattree

  • C. Bomken

  • S. Grundy

  • J. Gordon

  • D. Sugrue

  • N. Hill

  • L. Howard

Medical Centers

  • Haemophilia and Thrombosis Centre, University Hospital Wales, Cardiff

  • Queen Elizabeth University Hospital Glasgow, Glasgow, UK

  • Oxford University Hospital, Oxford,

  • Bristol‐Myers Squibb UK Ltd., Uxbridge, Middlesex

  • Birmingham HeartlandsHospital, Birmingham, UK

  • Sunderland Royal Hospital, Sunderland, UK

  • North Tyneside General Hospital, North Shields, Tyne & Wear

  • Health Economics & Outcomes Research

  • Ltd., Cardiff

  • Hammersmith Hospital, London, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Pulmonary embolism

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxyzine

  • apixaban

  • Warfarin

Outcome

  • N/A

Study Design

  • Randomized

  • Observational

  • Controlled

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved